Skip to content
2000
Volume 24, Issue 2
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Introduction

Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment for these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex.

Case Presentation

Here, we present two cases of effective use of hpCBD in both refractory and super-refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.

Conclusion

According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273304077240603115521
2024-06-21
2025-09-08

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273304077240603115521
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TrinkaE. LeitingerM. Management of Status epilepticus, refractory status epilepticus, and super-refractory status epilepticus.Continuum (Minneap. Minn.)202228255960210.1212/CON.0000000000001103 35393970
     [Google Scholar]
  2. BrophyG.M. BellR. ClaassenJ. Guidelines for the evaluation and management of status epilepticus.Neurocrit. Care201217132310.1007/s12028‑012‑9695‑z 22528274
     [Google Scholar]
  3. LowensteinD.H. The management of refractory status epilepticus: An update.Epilepsia200647s1Suppl. 1354010.1111/j.1528‑1167.2006.00658.x 17044824
     [Google Scholar]
  4. KirmaniB.F. AuK. AyariL. JohnM. ShettyP. DelorenzoR.J. Super-refractory status epilepticus: Prognosis and recent advances in management.Aging Dis.20211241097111910.14336/AD.2021.0302
     [Google Scholar]
  5. RaiS. DrislaneF.W. Treatment of refractory and super-refractory status epilepticus.Neurotherapeutics201815369771210.1007/s13311‑018‑0640‑5 29922905
     [Google Scholar]
  6. FarrokhS. BonJ. ErdmanM. TesoroE. Use of newer anticonvulsants for the treatment of status epilepticus.Pharmacotherapy201939329731610.1002/phar.2229 30723940
     [Google Scholar]
  7. OchoaJ.G. DoughertyM. PapanastassiouA. GidalB. MohamedI. VosslerD.G. Treatment of super-refractory status epilepticus: A review.Epilepsy Curr.202121640541510.1177/1535759721999670 33719651
     [Google Scholar]
  8. TambeS.M. MaliS. AminP.D. OliveiraM. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.J. Integr. Med.202321323624410.1016/j.joim.2023.03.004 36973157
     [Google Scholar]
  9. de AlmeidaD.L. DeviL.A. Diversity of molecular targets and signaling pathways for CBD.Pharmacol. Res. Perspect.202086e0068210.1002/prp2.682 33169541
     [Google Scholar]
  10. ZuroloE. IyerA.M. SplietW.G.M. CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.Neuroscience20101701284110.1016/j.neuroscience.2010.07.004 20621164
     [Google Scholar]
  11. HowlettA.C. AboodM.E. CB 1 and CB 2 receptor pharmacology.Adv. Pharmacol.20178016920610.1016/bs.apha.2017.03.007 28826534
     [Google Scholar]
  12. CostaB. GiagnoniG. FrankeC. TrovatoA.E. ColleoniM. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.Br. J. Pharmacol.2004143224725010.1038/sj.bjp.0705920 15313881
     [Google Scholar]
  13. De GregorioD. McLaughlinR.J. PosaL. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.Pain2019160113615010.1097/j.pain.0000000000001386 30157131
     [Google Scholar]
  14. TurkanisS.A. SmileyK.A. BorysH.K. OlsenD.M. KarlerR. An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats.Epilepsia197920435136310.1111/j.1528‑1157.1979.tb04815.x 477630
     [Google Scholar]
  15. PitkänenA. LukasiukK. DudekF.E. StaleyK.J. Epileptogenesis.Cold Spring Harb. Perspect. Med.2015510a02282210.1101/cshperspect.a022822
     [Google Scholar]
  16. BritchS.C. BabalonisS. WalshS.L. Cannabidiol: Pharmacology and therapeutic targets.Psychopharmacology (Berl.)2021238192810.1007/s00213‑020‑05712‑8 33221931
     [Google Scholar]
  17. AbbottsK.S.S. EwellT.R. ButterkleeH.M. Cannabidiol and cannabidiol metabolites: Pharmacokinetics, interaction with food, and influence on liver function.Nutrients20221410215210.3390/nu14102152
     [Google Scholar]
  18. TaylorL. GidalB. BlakeyG. TayoB. MorrisonG. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects.CNS Drugs201832111053106710.1007/s40263‑018‑0578‑5 30374683
     [Google Scholar]
  19. RajaramanR.R. SankarR. HussainS.A. Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus.Epilepsy Behav. Case Rep.20181014114410.1016/j.ebcr.2018.07.004
     [Google Scholar]
  20. DevinskyO. CrossJ.H. LauxL. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome.N. Engl. J. Med.2017376212011202010.1056/NEJMoa1611618 28538134
     [Google Scholar]
  21. StockingsE. ZagicD. CampbellG. Evidence for cannabis and cannabinoids for epilepsy: A systematic review of controlled and observational evidence.J. Neurol. Neurosurg. Psychiatry201889774175310.1136/jnnp‑2017‑317168 29511052
     [Google Scholar]
  22. RivaA D’OnofrioG PisatiA Cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy.Cannabis Cannabinoid Res2023can.2022.025510.1089/can.2022.0255 36862522
     [Google Scholar]
  23. FettaA. CrottiE. CampostriniE. Cannabidiol in the acute phase of febrile infection‐related epilepsy syndrome (FIRES).Epilepsia Open20238268569110.1002/epi4.12740 37042946
     [Google Scholar]
  24. DudaJ. ReinertJ.P. Cannabidiol in refractory status epilepticus: A review of clinical experiences.Seizure202210311511910.1016/j.seizure.2022.11.006 36399869
     [Google Scholar]
  25. VicinoW. MuccioliL. PondrelliF. Real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy.Seizure2023111394110.1016/j.seizure.2023.07.009 37506564
     [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273304077240603115521
Loading
Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) 24, 158 (2025); https://doi.org/10.2174/0118715273304077240603115521
/content/journals/cnsnddt/10.2174/0118715273304077240603115521
/content/journals/cnsnddt/10.2174/0118715273304077240603115521
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): anti-seizure medication; emergency; epilepsy; lennox-gastaut syndrome; seizure; Status epilepticus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test